185 related articles for article (PubMed ID: 17590511)
1. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
Müller T; Welnic J; Woitalla D; Muhlack S
Neurosci Lett; 2007 Jul; 422(2):119-22. PubMed ID: 17590511
[TBL] [Abstract][Full Text] [Related]
2. Rapid suppressing action of insulin-like growth factor-I (IGF-I) on GH release from anterior pituitary cells of goats.
Katoh K; Shimoguchi R; Ishiwata H; Obara Y
Domest Anim Endocrinol; 2004 Apr; 26(3):177-88. PubMed ID: 15036373
[TBL] [Abstract][Full Text] [Related]
3. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
4. Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Müller T; Muhlack S
J Neural Transm (Vienna); 2008 Jun; 115(6):851-5. PubMed ID: 18335161
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
Pellecchia MT; Pivonello R; Salvatore E; Faggiano A; Barone P; De Michele G; Lombardi G; Colao A; Filla A
Clin Endocrinol (Oxf); 2005 Apr; 62(4):428-33. PubMed ID: 15807873
[TBL] [Abstract][Full Text] [Related]
7. Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Müller T; Welnic J; Muhlack S
J Neural Transm (Vienna); 2007 Mar; 114(3):347-50. PubMed ID: 16932991
[TBL] [Abstract][Full Text] [Related]
8. Levodopa and executive performance in Parkinson's disease: a randomized study.
Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic dysfunction in Parkinson's disease patients.
Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
[TBL] [Abstract][Full Text] [Related]
10. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
Schaefer S; Vogt T; Nowak T; Kann PH;
J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558
[TBL] [Abstract][Full Text] [Related]
11. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
[TBL] [Abstract][Full Text] [Related]
13. Age-related differences in growth hormone (GH) regulation during strenuous exercise.
de Vries WR; Lambers M; van Zanten DP; Osman-Dualeh M; Maitimu I; Koppeschaar HP
Horm Metab Res; 2004 Jul; 36(7):501-5. PubMed ID: 15305235
[TBL] [Abstract][Full Text] [Related]
14. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
15. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Cornetta T; Palma S; Aprile I; Padua L; Tonali P; Testa A; Cozzi R
Cell Biol Toxicol; 2009 Aug; 25(4):321-30. PubMed ID: 18523852
[TBL] [Abstract][Full Text] [Related]
16. Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease.
Müller T; Muhlack S
J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):747-53. PubMed ID: 20478845
[TBL] [Abstract][Full Text] [Related]
17. An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis.
Fanciulli G; Tomasi PA; Giusti M; Bertoncelli A; Deplano A; Garrucciu G; Delitala G
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):148-51. PubMed ID: 18095239
[TBL] [Abstract][Full Text] [Related]
18. Modelling the hypothalamic control of growth hormone secretion.
MacGregor DJ; Leng G
J Neuroendocrinol; 2005 Dec; 17(12):788-803. PubMed ID: 16280026
[TBL] [Abstract][Full Text] [Related]
19. Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level.
Suárez C; Vela J; García-Tornadú I; Becu-Villalobos D
J Endocrinol; 2005 Apr; 185(1):165-72. PubMed ID: 15817837
[TBL] [Abstract][Full Text] [Related]
20. Photoperiod influences the central effects of ghrelin on food intake, GH and LH secretion in sheep.
Harrison JL; Miller DW; Findlay PA; Adam CL
Neuroendocrinology; 2008; 87(3):182-92. PubMed ID: 18073457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
